Phase I trial of intravesical gemcitabine in BCG-refractory transitional cell carcinoma of the bladder

被引：0
|
作者：
Dalbagni, G
Russo, P
Sheinfeld, J
Mazumdar, M
Tong, W
Rabbani, F
Donat, SM
Herr, HW
Sogani, P
Depalma, D
Bajorin, D
机构：
来源：
JOURNAL OF UROLOGY | 2002年 / 167卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：186 / 186
页数：1
相关论文
共 50 条
  • [31] A phase I trial of intra-vesical gemcitabine in the treatment of recurrent superficial transitional cell carcinoma of the bladder.
    Maddineni, SB
    Sangar, V
    Betts, CD
    O'Flynn, KJ
    Clarke, NW
    [J]. BRITISH JOURNAL OF CANCER, 2003, 88 : S63 - S63
  • [32] Gemcitabine and mitomycin intravesical therapy in patients with recurrent bladder cancer refractory to BCG
    Breyer, Benjamin N.
    Whitson, Jared M.
    Carroll, Peter R.
    Konety, Badrinath R.
    [J]. JOURNAL OF UROLOGY, 2008, 179 (04): : 122 - 122
  • [33] Risk of continued intravesical therapy and delayed cystectomy in BCG-refractory superficial bladder cancer: An investigational approach
    Luciani, LG
    Neulander, E
    Murphy, WM
    Wajsman, Z
    [J]. UROLOGY, 2001, 58 (03) : 376 - 379
  • [34] Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of bladder: Phase I-II study on marker lesions
    Serretta, V
    Galuffo, A
    Pavone, C
    Allegro, R
    Pavone-Macaluso, M
    [J]. UROLOGY, 2005, 65 (01) : 65 - 69
  • [35] Mycotic aortic aneurysm formation following intravesical BCG treatment for transitional cell carcinoma of the bladder
    Flynn, David
    Ogi, Akihiro
    Subedi, Shradha
    Langton, Jonathan
    Choong, Keat
    O'Donnell, Jill
    [J]. BMJ CASE REPORTS, 2021, 14 (11)
  • [36] DYSTROPHIC BLADDER WALL CALCIFICATIONS FOLLOWING INTRAVESICAL BCG TREATMENT FOR SUPERFICIAL TRANSITIONAL-CELL CARCINOMA OF BLADDER
    SPIRNAK, JP
    LUBKE, WL
    THOMPSON, IM
    LOPEZ, M
    [J]. UROLOGY, 1993, 42 (01) : 89 - 92
  • [37] Phase 1 dose-escalation trial of intravesical CG0070 for superficial transitional cell carcinoma (TCC) of the bladder after BCG failure
    Maslyar, Daniel J.
    McKiernan, James
    Nemunaitis, John
    Arseneau, James
    Stephenson, Joe
    Burke, James
    Neal, Kristina
    Aimi, Junko
    Lamm, Don
    [J]. JOURNAL OF IMMUNOTHERAPY, 2006, 29 (06) : 675 - 675
  • [38] UPDATED RESULTS OF THE COMBINED PHASE I/II TRIAL OF INTRAVESICAL NANOPARTICLE ALBUMIN-BOUND PACLITAXEL IN THE TREATMENT OF BCG REFRACTORY NON-MUSCLE INVASIVE TRANSITIONAL CELL CARCINOMA
    McKiernan, James M.
    Holder, Dara D.
    Kates, Max
    Badalato, Gina M.
    Barlow, Lamont J.
    RoyChoudhury, Arindam
    Petrylak, Daniel
    Benson, Mitchell C.
    [J]. JOURNAL OF UROLOGY, 2012, 187 (04): : E714 - E714
  • [39] PACLITAXEL PLUS HYALURONIC ACID BIOCONIUGATED FOR INTRAVESICAL THERAPY OF BCG REFRACTORY CARCINOMA IN SITU OF THE BLADDER: RESULTS OF A PHASE I STUDY
    Bassi, B. P. F.
    Volpe, V. A.
    D'agostino, D. D.
    Cappa, C. E.
    Sacco, S. E.
    Miglioranza, M. E.
    Passaro, P. G.
    Racioppi, R. M.
    [J]. EUROPEAN UROLOGY SUPPLEMENTS, 2010, 9 (02) : 94 - 94
  • [40] Adjuvant intravesical gemcitabine in intermediate or high risk transitional cell carcinoma of the bladder: A multicentre prospective study
    不详
    [J]. EUROPEAN UROLOGY SUPPLEMENTS, 2005, 4 (03) : 221 - 221
12345